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Objective: Uterine myoma is a common gynecologic disease. Myomectomy is selected to preserve the
uterus, and with recent advances in laparoscopic technology, laparoscopic myomectomy (LM) has
become a common treatment. However, myoma can recur after LM, and to date, reports on post-LM
recurrence rates and risk factors have been inconsistent. This retrospective study examines post-LM
recurrence rates and the possible risk factors for recurrence.
Materials and Methods: Between 1995 and 2010, 250 patients who underwent LM at a single institution
were followed from the postoperative sixth month to the ﬁfth year semiannually for recurrence by
ultrasound/magnetic resonance imaging (MRI). Mean age, body mass index (BMI), preoperative
gonadotropin-releasing hormone agonist (GnRHa) therapy, surgical time, blood loss, number of removed
myomas, and largest myoma diameter were compared between patients with recurrence and those
without. Recurrence rates were also investigated by individual risk factors, including patient age, GnRHa
therapy, number of removed myomas, and largest tumor diameter.
Results: Cumulative post-LM recurrence rates were 15.3%, 43.8%, and 62.1% at postoperative years 1, 3,
and 5, respectively. There were signiﬁcant differences in surgical time, blood loss, and number of
removed myomas between patients with recurrence and those without. Analysis of risk factors revealed
signiﬁcant correlation between recurrence rates and patient age, number of myomas, and myoma size.
Conclusion: Risk of post-LM recurrence increases over time. Risk factors are age, myoma size, and number
of tumors. Particular attention to recurrence is required for patients with uterine myomas of 10 cm
diameter, with numerous myomas, and those age 35 years or older.
Copyright  2012, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Myoma is a common gynecologic disease occurring in 20% of
females at the age of 30 years and older and 40% at the age of 40
years and older.1,2 Myomectomy is the surgical option selected to
preserve the uterus. Recently, laparoscopic myomectomy (LM) has
become a procedure of choice because it is less invasive. However,
myoma can recur after LM as after open surgery. Rossetti et al3 have
reported recurrence rates of 23% in open surgery and 27% in lapa-
roscopic surgery; there was no statistically signiﬁcant difference
between these rates. Yoo et al4 have reported recurrence rates of
11.7%, 36.1%, 52.9%, and 84.4%, respectively, at 1, 3, 5, and 8 years
after LM.4 They also reported that recurrence was less frequent in
patients with two or fewer myomas, myomas of a size comparable
to 13 weeks’ gestation, patients with no postoperative deliveries,d Gynecology, Kinki University
, Osaka 589-8511, Japan.
a).
ia-PaciﬁcAssociation forGynecologicEand patients younger than 35 years.4 They concluded that age,
number of tumors and size, presence of pelvic disease, and post-
operative parity were risk factors for recurrence. Nezhut et al5 have
reported recurrence rates of 31.7% and 51.4% in 3 and 5 years,
respectively, and Fedele et al6 have reported a recurrence rate of
51% at 5 years.
Overall, the results of studies on post-LM recurrence remain
inconsistent, and no study to date has thoroughly evaluated the
individual risk factors that may contribute to recurrence. Following
is a report of a retrospective investigation of recurrence rates and
possible risk factors for post-LM recurrence of myoma. This study
included a greater number of recurrent cases than has previously
been available.Materials and methods
A total of 334 patients underwent laparoscopic myomectomy at
a single hospital between January 1995 and December 2010.ndoscopyandMinimally InvasiveTherapy.PublishedbyElsevierTaiwanLLC.All rightsreserved.
Fig. 1. Cumulative recurrence rates after laparoscopic myomectomy (post-LM recur-
rence rates) were 15.3  2.5%, 43.8  4.5%, and 62.1  6.7% at postoperative years 1, 3,
and 5, respectively.
Table 2
Recurrence rates by risk factor.
Risk factor p value
Age <35 y Age 35 y
18.8% (range: 16e85) 35.2% (range: 58e165) <0.01
BMI < 25 BMI  25
28.0% (range: 60e214) 38.9% (range: 14e36) n.s.
Without GnRHa With GnRHa
26.9% (range: 49e182) 36.8% (range: 25e68) n.s.
Number of myomas ¼ 1 Number of myomas 2
23.0% (range: 26e113) 35.0% (range: 48e137) 0.04
Myoma diameter <10 cm Myoma diameter 10 cm
28.1% (range: 66e235) 53.5% (range: 8e15) 0.04
BMI ¼ body mass index; GnRHa ¼ gonadotropin-releasing hormone agonist;
n.s. ¼ no signiﬁcant difference.
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postoperatively, during which they were checked for recurrence
semiannually by methods including ultrasound and magnetic
resonance imaging (MRI). Recurrence was conﬁrmed when
a myoma with a diameter of 1 cm or larger was detected by
ultrasound or MRI.
Post-LM recurrence and repeat surgery rates were investigated
as well as the cumulative recurrence rates at 1, 3, and 5 years
postoperatively. The patients were divided in two groups, recurrent
and nonrecurrent, and potential risk factors for recurrence,
including mean age, body mass index (BMI), preoperative gonad-
otropin releasing hormone agonist (GnRHa) therapy, surgical time,
blood loss, number of removed myomas, and the largest myoma
diameter were compared. Recurrence rates were then compared
between each of the following subgroups: GnRHa therapy group
versus non-GnRHa group; group with one enucleated myoma
versus group with two or more enucleated myomas; group of age
35 years or older versus group younger than 35 years; and group
with the largest myoma diameter10 cm versus diameter <10 cm.
The patients with recurrence were subdivided into three groups
depending on recurrence time: <1 year, 1 year and <3 years, and
3 years and <5 years. The number of cases and mean myoma
diameter at recurrence were compared among the groups.
Surgical technique
With a uterine manipulator inserted, a pneumoperitoneum
needle was inserted through the umbilicus, and the pneumo-
peritoneum was accessed by the closed method. Subsequently, theTable 1
Comparison of results between the recurrence and nonrecurrence groups.
Overall R
n ¼ 250 n
Age (y) (range) 36.6  5.1 (26e51) 3
Body mass index (kg/m2) (range) 21.4  3.0 (16.4e35.7) 2
GnRH (%) (range) 27.2 (68/250)
Surgical time (min) (range) 155  60 (65e422)
Blood loss (mL) (range) 183  210 (9e1250) 2
Number of myomas (range) 3.1  3.5 (1e31)
Largest diameter (cm) (range) 6.8  2.5 (1.5e14.8)
GnRH ¼ gonadotropin-releasing hormone; n.s. ¼ no signiﬁcant difference.ﬁrst trocar was inserted through the umbilicus and the laparoscope
was inserted. The second and third trocars were placed in the left
and right lower abdomen, and the fourth trocar was placed on the
left side of the umbilicus. The size of the trocars was 5 mm except
for the fourth, which was 12 mm for the retrieval of myomas and
intracorporeal suturing. To reduce blood loss, vasopressin diluted
100-fold was locally injected through the surface of myomas.7,8 The
myometriumwas incised with an ultrasonic knife and the myomas
were grasped, pulled, and enucleated with a borer. The uterine
incision was closed in two to three layers with 1-Vicryl suture on
a CT-1 needle (Johnson & Johnson). Enucleated myoma nodules
were then retrieved from the body with a morcellator. The surgery
was completed after hemostasis was conﬁrmed, the intraperitoneal
cavity was washed, and a Sepraﬁlm (genzyme) hyaluronic acid/
carboxymethylcellulose membrane was applied to the incision
sites.9
Statistical analyses
The Kaplan-Meier method was used for evaluating the cumu-
lative recurrence rates. For a comparison of the rates between the
two groups, a Chi-square test was performed. Results were statis-
tically signiﬁcant when p < 0.05.
Results
There were 74 patients who had recurrent myomas during the
postoperative study period, for an overall recurrence rate of 29.6%
(74 of 250). The repeat surgery rate was 2.4% (6 of 250). The
cumulative recurrence rates were 15.3%, 43.8%, and 62.1% at
postoperative years 1, 3, and 5, respectively (Fig. 1). The compar-
ison between the recurrence and nonrecurrence groups is shown
in Table 1. There was no signiﬁcant difference in mean age (37.5
years vs. 36.1 years); mean BMI (22.1 vs. 21.3); administration of
GnRHa (33.8% vs. 24.4); or the mean largest myoma diameter
(7.0 cm vs. 6.6 cm). There were signiﬁcant differences in the mean
surgical time and mean blood loss (176 minutes vs. 151 minutesecurrence group Nonrecurrence group p value
¼ 74 n ¼ 176
7.5  4.6 (27e46) 36.1  5.0 (26e51) n.s.
2.1  3.4 (16.6e32.9) 21.3  3.1 (16.4e35.7) n.s.
33.8 (25/74) 24.4 (43/176) n.s.
176  62 (80e422) 151  59 (65e405) <0.01
49  258 (10e1250) 156  174 (9e800) <0.01
3.7  3.4 (1e16) 2.7  3.4 (1e31) 0.03
7.0  2.1 (2.4e12.1) 6.6  2.4 (1.5e14.8) n.s.
Table 3
Number of recurrence cases and mean myoma diameter at recurrence in the three
recurrence groups.
Recurrence time <1 y 1 y and <3 y 3 y and <5 y Total
Number of cases (%) 28 (37.8) 38 (51.4) 8 (10.8) 74
Mean diameter at
recurrence (cm) 
standard deviation
2.2  1.1 2.2  1.3 2.4  1.0 2.2  1.2
M. Shiota et al. / Gynecology and Minimally Invasive Therapy 1 (2012) 34e3636and 249 mL vs. 156 mL), and in the mean number of enucleated
myomas (3.7 vs. 2.7).
Table 2 summarizes the recurrence rate by risk factor. No
signiﬁcant difference was found in the recurrence rate after
administration of GnRHa therapy (36.8% vs. 26.9%). Signiﬁcant
differences in post-LM recurrence rates were conﬁrmed between
patients with two or more myomas and those with single lesions
(35.8% vs. 23.0%) and between patients who were age 35 years and
older and those who were younger than 35 years (35.2% vs. 18.8%).
Patients in whom the largest enucleated myoma was 10 cm also
had a signiﬁcantly higher rate of recurrence than those with
myomas <10 cm diameter (53.5% vs. 28.1%).
Table 3 summarizes the number of recurrence cases and the
mean myoma diameter at recurrence in the three recurrence
groups. The number was 28 (37.8%), and the mean diameter was
2.2 cm in the group with recurrence in <1 year, 38 (51.4%) and
2.2 cm in the group1 year and<3 years, and 8 (10.8 %) and 2.4 cm
in the group 3 years and <5 years.
Discussion
LM is less invasive and as safe as openmyomectomy.3,10e14 LM is
increasingly performed in our facility because it is less invasive.
However, there have been few studies of post-LM recurrence rates.
This study has investigated overall recurrence rates and the
potential risk factors for recurrence. The cumulative recurrence rate
was 62.1% at 5 years postoperatively. This rate is comparable to 5-
year recurrence rates reported previously. Although post-LM
recurrence is frequent, the repeat surgery rate in the current
study was only 2.4%, which indicates that most of the recurrent
myomas are small and asymptomatic, therefore requiring no
further intervention.
Among the potential risk factors for recurrence, surgical time,
blood loss, and the number of enucleated myomas were signiﬁ-
cantly higher in the patients with recurrence than in the non-
recurrence group. Previous studies have also reported that a larger
number of enucleated myomas is associated with a higher recur-
rence rate. The larger volumes of blood loss and longer surgical
times suggest that the surgical procedures were challenging, likely
due to the presence of large or numerous myomas. Thus, larger
number and larger size of myomas are thought to be related to the
higher recurrence rates in these patients.
Regarding the individual risk factors, the recurrence rate was
signiﬁcantly higher in the group with two or more enucleated
myomas, in patients age 35 years and older, and in cases where the
diameter of the largest myoma was 10 cm. Obesity and preoper-
ative GnRHa therapy did not affect the recurrence rates. GnRHa is
administered preoperatively in some instances to reduce the size of
myomas. Reductions of myoma volumes by approximately 40% can
be expected after four to six courses of GnRHa administration.15
However, preoperative GnRHa therapy has been reported to have
a signiﬁcantly higher rate of postoperative recurrence (37.5% vs.14.8%).3 It is proposed that this is because the shrunken myomas
may be overlooked at the time of surgery and left in the uterus.
Although particularly small myomas may become indistinct after
GnRHa therapy, and the possibility of overlooked myomas cannot
be denied, the current study investigates the risk of recurrence
without consideration of the correlation between overlooked
myomas and postoperative recurrence. The authors of the current
study have previously found that GnRHa therapy does not increase
the risk of postoperative myoma recurrence if all myomas
conﬁrmed preoperatively by MRI were enucleated, and this study,
in which a greater number of cases was evaluated, has again
demonstrated that preoperative GnRHa therapy does not increase
the risk of postoperative recurrence after LM.16
In conclusion, the rate of recurrence of myoma after LM
increases over time. The risk factors related to recurrence are
patient age, myoma size, and number of tumors. Particular atten-
tion to the increased risk of recurrence is required for patients with
uterine myoma >10 cm, numerous myomas, and in patients who
are 35 years or older.
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